
S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
ASCEMBL Trial Design and Primary Endpoint
Elias Jabbour outlines the randomized phase 3 ASCEMBL trial comparing asciminib versus bosutinib in patients after ≥2 TKIs.
Play episode from 02:15
Transcript


